-+ 0.00%
-+ 0.00%
-+ 0.00%

Helus Pharma backs White House executive order to speed psychedelic therapy pathways

PUBT·04/20/2026 12:15:39
Listen to the news
Helus Pharma backs White House executive order to speed psychedelic therapy pathways
  • Helus Pharma, Cybin operating name, welcomed White House Executive Order aimed at accelerating psychedelic research, regulatory pathways, patient access.
  • Interim CEO Eric So said policy momentum matters, but outcomes will depend on clinical evidence, ability to deliver safe, reliable treatments at scale.
  • Helus cited potential for prioritized FDA review for psychedelic therapies with Breakthrough Therapy designation.
  • Company said lead program HLP003 is in Phase 3 for adjunctive treatment of major depressive disorder, holding FDA Breakthrough Therapy designation.
  • Helus said it expects policy actions to support development of new options for major depressive disorder, generalized anxiety disorder.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200815PRIMZONEFULLFEED9692973) on April 20, 2026, and is solely responsible for the information contained therein.